ALNYLAM PHARMA
ALNYLAM PHARMA operates in Diversified Metals & Mining.
ALNYLAM PHARMA (DUL) - Total Assets
Latest total assets as of September 2024: €4.21 Billion EUR
Based on the latest financial reports, ALNYLAM PHARMA (DUL) holds total assets worth €4.21 Billion EUR as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ALNYLAM PHARMA - Total Assets Trend (2016–2023)
This chart illustrates how ALNYLAM PHARMA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ALNYLAM PHARMA - Asset Composition Analysis
Current Asset Composition (December 2023)
ALNYLAM PHARMA's total assets of €4.21 Billion consist of 77.9% current assets and 22.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 21.2% |
| Accounts Receivable | €327.79 Million | 8.6% |
| Inventory | €89.15 Million | 2.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2023)
This chart illustrates how ALNYLAM PHARMA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ALNYLAM PHARMA's current assets represent 77.9% of total assets in 2023, an increase from 53.2% in 2016.
- Cash Position: Cash and equivalents constituted 21.2% of total assets in 2023, up from 15.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 8.6% of total assets.
ALNYLAM PHARMA Competitors by Total Assets
Key competitors of ALNYLAM PHARMA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
ALNYLAM PHARMA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - ALNYLAM PHARMA generates 0.48x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ALNYLAM PHARMA is currently not profitable relative to its asset base.
ALNYLAM PHARMA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.75 | 3.14 | 4.87 |
| Quick Ratio | 2.69 | 3.04 | 4.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.13 Billion | € 2.04 Billion | € 1.36 Billion |
ALNYLAM PHARMA - Advanced Valuation Insights
This section examines the relationship between ALNYLAM PHARMA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 8.0% |
| Total Assets | €3.83 Billion |
| Market Capitalization | $2.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values ALNYLAM PHARMA's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: ALNYLAM PHARMA's assets grew by 8.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for ALNYLAM PHARMA (2016–2023)
The table below shows the annual total assets of ALNYLAM PHARMA from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €3.83 Billion | +7.99% |
| 2022-12-31 | €3.55 Billion | -2.66% |
| 2021-12-31 | €3.64 Billion | +6.93% |
| 2020-12-31 | €3.41 Billion | +42.25% |
| 2019-12-31 | €2.40 Billion | +52.09% |
| 2018-12-31 | €1.57 Billion | -21.05% |
| 2017-12-31 | €1.99 Billion | +57.96% |
| 2016-12-31 | €1.26 Billion | -- |